Debate

DOI: 10.4244/EIJ-E-24-00013

Is bivalirudin ready for a comeback? Pros and cons

Gregg W. Stone, MD; Oludamilola Akinmolayemi, MD, MPH; Rod H. Stables, DM, FRCP

Introduction

Bivalirudin, a direct thrombin inhibitor, has been extensively studied as an alternative option for anticoagulation in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). Studies comparing bivalirudin to heparin yielded mixed results, with signals of concern about acute stent thrombosis; in addition, the perceived lower bleeding risk associated with bivalirudin has been attributed to the increased use of glycoprotein IIb/IIIa inhibitors (GPI) in heparin arms, suggesting potential bias in the comparison. Nevertheless, more recent trials and meta-analyses showed that bivalirudin was associated with similar or even lower risks of death and ischaemic events – including stent thrombosis – as well as less bleeding compared to heparin. In the light of accumulating evidence, whether bivalirudin should be considered as the preferred option for anticoagulation in ACS patients undergoing PCI is an area of ongoing debate.

Pros

Gregg W. Stone, MD; Oludamilola Akinmolayemi, MD, MPH

The optimal anticoagulation regimen during PCI in ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) patients would reduce the risks of death, stent thrombosis, and reinfarction while minimising bleeding complications....

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 15
Aug 5, 2024
Volume 20 Number 15
View full issue


Key metrics

Suggested by Cory

10.4244/EIJV9I4A69 Aug 23, 2013
Antithrombotic therapy in PCI: why not heparin?
Shahzad A et al
free
Trending articles
310.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
76.25

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
42

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved